临床实践中抗拓扑异构酶I(Scl-70)抗体假阳性结果:来自硬皮病转诊中心的病例系列
在硬皮病转诊中心,52例转诊前抗Scl-70抗体阳性但不符合可分类系统性硬化症(SSc)标准的患者中,经免疫扩散法复测48例(92.3%)阴性、4例(7.7%)阳性;免疫扩散法阴性的48例中43例(89.6%)基于2013年ACR/EULAR SSc分类标准仅有≤1项临床标准条目,但21例(43.8%)曾接受胸部CT、14例(29.2%)曾接受超声心动图检查。作者结论认为临床常用商业实验室的抗Scl-70抗体检测可产生假阳性结果,可导致患者焦虑以及不必要的转诊和诊断性检查。
要点
- 转诊前抗Scl-70抗体阳性但不符合可分类SSc标准的52例患者中,免疫扩散法复测48例(92.3%)阴性、4例(7.7%)阳性。
- 免疫扩散法阴性的48例中,18例(37.5%)间接免疫荧光ANA阴性,33例(68.8%)无雷诺现象,43例(89.6%)基于2013年ACR/EULAR SSc分类标准仅有≤1项临床标准条目。
- 免疫扩散法阴性的48例中,21例(43.8%)曾接受胸部CT、14例(29.2%)曾接受超声心动图检查。
核心结论
- 临床常用商业实验室的抗Scl-70抗体检测可产生假阳性结果,这些结果可导致患者焦虑以及不必要的转诊和诊断性检查。
研究设计与样本
- 本研究为来自硬皮病转诊中心的病例系列,纳入转诊前抗Scl-70抗体阳性但基于临床标准不符合可分类SSc、由风湿科医生评估的患者,邀请其接受免疫扩散法抗Scl-70抗体检测,并记录评估时人口学与临床特征、复习病历中的诊断检查结果。
- 共52例患者在8年期间入组。
主要发现
- 52例中免疫扩散法抗Scl-70抗体阴性48例(92.3%)、阳性4例(7.7%)。
- 免疫扩散法阴性的48例中,18例(37.5%)间接免疫荧光ANA阴性,33例(68.8%)无雷诺现象,43例(89.6%)基于2013年ACR/EULAR SSc分类标准仅有≤1项临床标准条目。
- 免疫扩散法阴性的48例中,21例(43.8%)曾接受胸部CT,14例(29.2%)曾接受超声心动图检查。
- 共23例患者至少有1次随访门诊;免疫扩散法阳性的4例中3例、免疫扩散法阴性的19例中0例在随访期间出现足够标准而被分类为SSc。
关键数值与推荐
- 免疫扩散法复测:48/52例(92.3%)阴性,4/52例(7.7%)阳性。
- 免疫扩散法阴性48例中,18例(37.5%)间接免疫荧光ANA阴性,33例(68.8%)无雷诺现象,43例(89.6%)基于2013年ACR/EULAR SSc分类标准仅有≤1项临床标准条目。
- 免疫扩散法阴性48例中,21例(43.8%)曾接受胸部CT,14例(29.2%)曾接受超声心动图检查。
- 随访期间:免疫扩散法阳性4例中3例被分类为SSc,免疫扩散法阴性19例中0例被分类为SSc。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine if some patients who tested positive for anti-Scl-70 antibody in clinical practice, but did not have classifiable systemic sclerosis, were negative for anti-Scl-70 antibody by the more specific immunodiffusion method of testing. METHODS: Patients evaluated by a rheumatologist at a Scleroderma referral center who had tested positive for anti-Scl-70 antibody prior to referral, but did not have classifiable SSc based on clinical criteria, were invited to undergo testing for anti-Scl-70 antibody by immunodiffusion. Patient demographics and clinical features were recorded at the time of their evaluation, and diagnostic testing results were reviewed using the medical records. RESULTS: 52 patients were enrolled over an 8-year period, with 48 (92.3%) testing negative and 4 (7.7%) testing positive for anti-Scl-70 antibody by immunodiffusion. Of the 48 patients who tested negative, 18 (37.5%) tested negative for ANA by indirect immunofluorescence, 33 (68.8%) did not have Raynaud's phenomenon, and 43 (89.6%) had ≤1 clinical criteria items based on the 2013 ACR/EULAR SSc classification criteria. Nevertheless, 21 (43.8%) patients who were negative for anti-Scl-70 antibody by immunodiffusion had undergone a chest CT and 14 (29.2%) had undergone an echocardiogram. A total of 23 patients had at least one follow up clinic visit. 3 out of 4 patients who were positive for anti-Scl-70 antibody by immunodiffusion, but none of the 19 patients who tested negative by immunodiffusion, developed sufficient criteria during follow up to be classified as SSc. CONCLUSION: Assays for anti-Scl-70 antibody in commercial laboratories that are commonly utilized in clinical practice can produce false positive results. These results can lead to angst for patients, as well as unnecessary referrals and diagnostic evaluations.
引用
- Lam BH, Assassi S, Charles J, et al. False positive anti-Topoisomerase I (Scl-70) antibody results in clinical practice: A case series from a scleroderma referral center. Semin Arthritis Rheum. 2022. PMID: 35753143. doi:10.1016/j.semarthrit.2022.152052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。